Clinical significance of survivin and VEGF mRNA detection in the cell fraction of the peripheral blood in non-small cell lung cancer patients before and after surgery

Lung Cancer

Volumn 81, Issue 2, 2013, Pages 273-279

  Tang, X P ^a   Li, J ^a   Yu, L C ^a   Chen, Y C ^b   Shi, S B ^a   Zhu, L R ^a   Chen, P ^a  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

Non small cell lung cancer; Prognosis; Quantitative real time PCR; Survivin; VEGF

Indexed keywords

MESSENGER RNA; SURVIVIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL FRACTIONATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

NON-SMALL CELL LUNG CANCER; PROGNOSIS; QUANTITATIVE REAL-TIME PCR; SURVIVIN; VEGF;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879880535     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.05.005     Document Type: Article

References (22)

1. Mountain C.F. Revision in the international system for stage lung cancer. Chest 1997, 111:1710-1717.
2. Martini N., Bains M.S., Burt M.E., Zakowski M.T., McCormack P., Rusch V.W., et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995, 109:120-129.
3. Benlloch S., Galbis-Caravajal J.M., Alenda C., Peiro F.M., Sanchez-Ronco M., Rodriguez-Paniagua J.M., et al. Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases. Ann Oncol 2009, 20:91-97.
4. Chen T.F., Jiang G.L., Fu X.L., Wang L.T., Qian H., Wu K.L., et al. CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor. Lung Cancer 2007, 56:105-114.
5. Chen T.-L., Chang M.-Y., Huang S.-Y., Sheu C.-C., Kao E.-L., Cheng Y.-J., et al. Overexpression of circulating C-Met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest 2005, 128:1453-1460.
6. Velms F.A., Diepstra J.H., Cornelissen I.M., Ruers T.J.M., Ligtenberg M.J.L., Punt C.J.A., et al. Limitations of cytokeratin 20 RT-PCR to detect disseminated tumor cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumor tissue. Mol Pathol 2002, 55:156-163.
7. Xi L., Nicastin D.G., El-Hefnawy T., Hughes S.J., Luketich J.D., Godfrey T.E. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem 2007, 53:1206-1215.
8. Bustin S.A., Mueller R. Real-time reverse transcription PCR (Qrt PCR) and its potential use in clinical diagnosis. Clin Sci (Lond) 2005, 109:365-379.
9. Ambrosini G., Adida C., Alfieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921.
10. Altieri D.C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trend Mol Med 2001, 7:543-547.
11. Yie S.M., Lou B., Ye S.R., He X., Gao M., Xie K., et al. Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer. Lung Cancer 2009, 63:284-290.
12. Scappaticei F.A. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002, 20:3906-3927.
13. Tamura M., Ohta Y., Kajita T., Kimura K., Go T., Oda M., et al. Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small cell lung cancer. Oncol Rep 2001, 8:1097-1102.
14. Tamur M., Ohta Y., Nakamura H., Oda M., Watanabe G. Diagnostic value of plasma vascular endothelial growth factor as a tumor marker in patients with non-small cell lung cancer. Int J Biol Markers 2002, 17:275-279.
15. AJCC cancer staging manual 2002, Springer-Verlag, New York. 6th ed. F.L. Green, D.L. Page, I.D. Fleming (Eds.).
16. -δδCT method. Method 2001, 25:402-408.
17. Fidler I.J. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revised. Nat Rev Caner 2003, 3:453-458.
18. O'sullivan G.C., Collins J.K., Kelly J., Morgan J., Madden M., Shanahan F., et al. Micrometastases: marker of metastatic potential or evidence of residual disease?. Gut 1997, 40:512-515.
19. Laack E., Kohler A., Kugler C., Dierlamm T., Knuffmann C., Vohwinkel G., et al. Pretreatment serum levels of matrix methalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002, 13:1551-1557.
20. Dudek A.Z., Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 2005, 23:193-200.
21. Chakra M., Pujol J.L., Lmy P.-J., Bozonnat M.C., Quantin X., Jacot W., et al. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol 2008, 3:1119-1125.
22. Setoyama T., Natsugoe S., Okumura H., Matsumoto M., Uchikado Y., Ishigami S., et al. Carcinoembryonic antigen messenger RNA expression in blood predicts recurrence in esophageal cancer. Clin Cancer Res 2006, 12:5972-5977.